Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9)

被引:0
|
作者
DeLeon, JH [1 ]
Martell, KJ [1 ]
Vatsis, KP [1 ]
Weber, WW [1 ]
机构
[1] UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Three N-acetyltransferase genes (NAT*) were detected in inbred parental and congenic mice, Direct sequencing of NAT2* and liver cytosolic N-acetylation activity determinations with NAT2-specific (p-aminobenzoic acid) and NAT2-selective (2-aminofluorene) substrates have established that the acetylator congenic A.B6 and B6.A mice are genotypically and phenotypically identical to the parental B6 (''wild-type''; rapid acetylator) and A (mutant; slow acetylator) mice, respectively, from which they originated, The apparent K-M for p-aminobenzoic acid and thermal inactivation rates determined with liver cytosol from the mutant (A and B6.A) mice were 3-fold and one order of magnitude higher than the corresponding values with liver cytosol from the wild-type (B6 and A,B6) strains, Northern blotting and immunoblotting revealed hepatic NAT2 mRNA and protein bands of equal size and intensity, regardless of the NAT2* genotype or phenotype of the animals. Incubation of liver cytosol from mutant A and B6.A mice at 37 degrees C for 6 hr resulted in virtual cessation of p-aminobenzoate N-acetylation activity, whereas the steady-state level of immunoreactive NAT2 remained unchanged, The results indicate that the amino acid change (N991) in mutant NAT2* from slow acetylator mice does not hinder the synthesis of hepatic NAT2 protein, but, rather, leads to production of a conformationally modified NAT2 molecule that resists degradation by tissue proteases but is labile and catalytically impaired.
引用
收藏
页码:1354 / 1361
页数:8
相关论文
共 50 条
  • [1] Slow N-acetyltransferase 2 (NAT2) acetylation state as a susceptibility factor for bladder cancer
    Reckwitz, T
    Weistenhöfer, W
    Farker, K
    Prior, V
    Seidel, T
    Schubert, J
    Zumbe, J
    Dietrich, H
    Golka, K
    Schulze, H
    JOURNAL OF UROLOGY, 2003, 169 (04): : 140 - 140
  • [2] N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice
    Loehle, Jennifer A.
    Cornish, Valerie
    Wakefield, Larissa
    Doll, Mark A.
    Neale, Jason R.
    Zang, Yu
    Sim, Edith
    Hein, David W.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (02): : 724 - 728
  • [3] Comparison of acetylation phenotype with genotype coding for N-acetyltransferase (NAT2) in children
    Zielinska, E
    Bodalski, J
    Niewiarowski, W
    Bolanowski, W
    Matusiak, I
    PEDIATRIC RESEARCH, 1999, 45 (03) : 403 - 408
  • [4] Comparison of Acetylation Phenotype with Genotype Coding for N-Acetyltransferase (NAT2) in Children
    Elżbieta Zielińska
    Jerzy Bodalski
    Wojciech Niewiarowski
    Wojciech Bolanowski
    Iwona Matusiak
    Pediatric Research, 1999, 45 : 403 - 408
  • [5] Localization of polymorphic N-acetyltransferase (NAT2) in tissues of inbred mice
    Stanley, LA
    Mills, IG
    Sim, E
    PHARMACOGENETICS, 1997, 7 (02): : 121 - 130
  • [6] Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis
    Woolhouse, NM
    Qureshi, MM
    Bastaki, SMA
    Patel, M
    Abdulrazzaq, Y
    Bayoumi, RAL
    PHARMACOGENETICS, 1997, 7 (01): : 73 - 82
  • [7] ETHNIC DISTRIBUTION OF SLOW ACETYLATOR MUTATIONS IN THE POLYMORPHIC N-ACETYLTRANSFERASE (NAT2) GENE
    LIN, HJ
    HAN, CY
    LIN, BK
    HARDY, S
    PHARMACOGENETICS, 1994, 4 (03): : 125 - 134
  • [8] Ultra-slow N-acetyltransferase 2 (NAT2) and relapses in bladder cancer patients
    Selinski, Silvia
    Geis, Berit C.
    Gerullis, Holger
    Otto, Thomas
    Roth, Emanuel
    Volkert, Frank
    Ovsiannikov, Daniel
    Salem, Johannes
    Moormann, Oliver
    Niedner, Hartmut
    Blaszkewicz, Meinolf
    Hengstler, Jan G.
    Golka, Klaus
    TOXICOLOGY LETTERS, 2017, 280 : S240 - S241
  • [9] Ultra-slow N-acetyltransferase 2 (NAT2) and prognosis in bladder cancer patients
    Selinski, S.
    Geis, B.
    Gerullis, H.
    Otto, T.
    Roth, E.
    Volkert, F.
    Ovsiannikov, D.
    Salem, J.
    Moormann, O.
    Niedner, H.
    Blaszkewicz, M.
    Hengstler, J. G.
    Golka, K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S57 - S57
  • [10] Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population
    Aynacioglu, AS
    Cascorbi, I
    Mrozikiewicz, PM
    Roots, I
    PHARMACOGENETICS, 1997, 7 (04): : 327 - 331